Business context and reporting period
GlycoMimetics, Inc. filed this Form 10-K for the fiscal year ended December 31, 2016. The request metadata names Crescent BioPharma, Inc.; that does not match the registrant identified in the filing. GlycoMimetics (NASDAQ: GLYC) is a clinical-stage biotechnology company with no approved products or product-sale revenue. Its programs include rivipansel, licensed to Pfizer, and internally developed GMI-1271 and GMI-1359.
Key financial metrics
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $18,500 | $20.07 million |
| Research and development | $23.28 million | $25.05 million |
| General and administrative | $8.65 million | $7.81 million |
| Net loss | $31.81 million | $12.77 million |
| Basic and diluted loss per share | $1.50 | $0.67 |
| Operating cash used | $29.73 million | $8.24 million |
| Cash and cash equivalents at year-end | $40.04 million | $46.80 million |
Revenue in 2016 was immaterial and primarily reflected research-grant activity; the company reported no Pfizer milestone or royalty payment that year. The 2015 revenue included a $20 million Pfizer milestone. Gross margin and product margins are not meaningful because the company had no product sales. It reported total assets of $42.39 million, liabilities of $7.09 million and stockholders’ equity of $35.30 million at year-end. The filing reports no borrowings; it discloses $6.92 million of future minimum operating-lease payments.
Material changes versus the prior comparable period
- Net loss widened by $19.04 million, chiefly reflecting the absence of the 2015 Pfizer milestone revenue; operating expenses declined modestly overall.
- R&D expense fell 7% as lower manufacturing and formulation costs and no recurring University of Basel milestone fee more than offset increased clinical-development costs for GMI-1271 and GMI-1359.
- G&A expense rose 11%, primarily from higher personnel-related and stock-based compensation costs.
- Operating cash use increased substantially. The company raised $23.60 million net through a June 2016 public offering and its at-the-market facility; year-end cash nevertheless declined by $6.76 million.
Outlook, risks and notable items
- Management estimated that year-end cash would fund operating expenses and capital needs into the second quarter of 2018, excluding potential Pfizer milestones. The estimate is subject to uncertainty; no other committed external funding source was disclosed.
- The company expects continued losses and significant development spending, and does not assure future profitability. Additional financing may be needed and could dilute shareholders or require licensing rights.
- GMI-1271’s AML study reported preliminary complete-remission rates of 45% among 33 relapsed or refractory participants pooled across trial portions, and 73% among 11 newly diagnosed participants aged 60 or older. These are early clinical findings, not proof of efficacy; further study and enrollment were planned.
- In an earlier 76-patient rivipansel Phase 2 study, several time-to-resolution and hospital-stay measures favored treatment but were not statistically significant; opioid use was reduced 83% (p=0.01). Pfizer is responsible for further development, and projected Phase 3 enrollment completion was the second half of 2018.
- Key risks include clinical-trial failure or delay, dependence on Pfizer for rivipansel milestones and royalties, financing needs, competition, regulatory and reimbursement uncertainty, and patent protection. The company disclosed no material legal proceedings. Management reported effective disclosure controls and internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: the filing is GlycoMimetics, Inc. (GLYC), not Crescent BioPharma, Inc.
- Review the audited statements and cash-flow detail, particularly the sharp increase in operating cash use and the assumptions behind the Q2 2018 runway estimate.
- Check subsequent clinical-trial updates and enrollment against the filing’s 2017 and 2018 expectations; assess the limitations of the preliminary GMI-1271 results.
- Verify Pfizer’s continuing development progress and any milestone eligibility, and account for the University of Basel’s contractual 10% share of specified rivipansel milestone and royalty receipts.
- Consider dilution: the company issued equity in 2016 and disclosed additional at-the-market sales after year-end.